LY4395089 + Mirikizumab for Crohn's Disease

This trial tests a new combination treatment for individuals with moderate to severe Crohn's disease, a condition that causes inflammation in the digestive tract. Researchers aim to determine if combining LY4395089, an experimental drug, with mirikizumab is more effective than using mirikizumab alone. The study will last about 62 weeks, with different groups receiving different treatments for comparison. Individuals who have had Crohn's disease for some time and are on stable doses of certain diabetes medications might be suitable candidates for this trial. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in Crohn's disease treatment.

The trial allows participants to continue taking certain medications like GLP-1 receptor agonists if they are on a stable dose. However, the protocol does not specify about other medications, so it's best to discuss your current medications with the trial team.

Research has shown that mirikizumab, one of the treatments in the trial, has undergone thorough safety evaluation. Long-term use of mirikizumab in individuals with Crohn's disease has consistently demonstrated safety over several years. Specifically, one study found that over 90% of patients who stopped using steroids remained in remission for three years without new safety issues. Common side effects in studies were mild to moderate and manageable.

Regarding LY4395089, less detailed safety information is available. However, its progression to a phase 2 trial indicates it passed initial safety tests in humans, demonstrating sufficient safety in earlier studies. Combining it with mirikizumab aims to enhance treatment without adding significant risks.

Researchers are excited about these treatments for Crohn's Disease because they offer new approaches compared to current options, like biologics such as infliximab and adalimumab. LY4395089 is a novel oral treatment that, when combined with mirikizumab, could provide a more targeted approach to managing inflammation. Mirikizumab, an IL-23 inhibitor, is administered intravenously and then subcutaneously, which might offer more sustained relief for patients who respond well. This combination has the potential to enhance efficacy and improve patient outcomes by leveraging different mechanisms of action and routes of administration.

Research has shown that mirikizumab effectively treats Crohn's disease. Specifically, studies found that over 92% of patients who were symptom-free remained so after two years of treatment. Additionally, about 60-67% of patients experienced significant symptom improvement. In this trial, some participants will receive mirikizumab alone, while others will receive a combination of mirikizumab and LY4395089. LY4395089 reduces inflammation, and its use with mirikizumab may yield even better results by more effectively addressing gut inflammation. This combination aims to provide strong, long-lasting control of Crohn's disease symptoms.¹²⁵⁶⁷